ZEVALIN Drug Profile

Summary for Tradename: ZEVALIN

High Confidence Patents:	27
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for ZEVALIN

Recent Clinical Trials for ZEVALIN

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
TerSera Therapeutics	Phase 2
TerSera Therapeutics LLC	Phase 2
JDP Therapeutics, Inc.	Phase 2

See all ZEVALIN clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ZEVALIN Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ZEVALIN Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Acrotech Biopharma Inc.	ZEVALIN	ibritumomab tiuxetan	Injection	125019	5,736,137	2013-11-03	DrugPatentWatch analysis and company disclosures
Acrotech Biopharma Inc.	ZEVALIN	ibritumomab tiuxetan	Injection	125019	5,776,456	2015-06-07	DrugPatentWatch analysis and company disclosures
Acrotech Biopharma Inc.	ZEVALIN	ibritumomab tiuxetan	Injection	125019	5,843,439	2015-06-07	DrugPatentWatch analysis and company disclosures
Acrotech Biopharma Inc.	ZEVALIN	ibritumomab tiuxetan	Injection	125019	6,207,858	2019-03-03	DrugPatentWatch analysis and company disclosures
Acrotech Biopharma Inc.	ZEVALIN	ibritumomab tiuxetan	Injection	125019	6,296,839	2020-03-30	DrugPatentWatch analysis and company disclosures
Acrotech Biopharma Inc.	ZEVALIN	ibritumomab tiuxetan	Injection	125019	6,399,061	2015-06-07	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ZEVALIN Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Acrotech Biopharma Inc.	ZEVALIN	ibritumomab tiuxetan	Injection	125019	10,016,338	2036-12-20	Patent claims search
Acrotech Biopharma Inc.	ZEVALIN	ibritumomab tiuxetan	Injection	125019	10,016,412	2036-12-09	Patent claims search
Acrotech Biopharma Inc.	ZEVALIN	ibritumomab tiuxetan	Injection	125019	10,093,934	2036-07-03	Patent claims search
Acrotech Biopharma Inc.	ZEVALIN	ibritumomab tiuxetan	Injection	125019	10,117,943	2033-05-03	Patent claims search
Acrotech Biopharma Inc.	ZEVALIN	ibritumomab tiuxetan	Injection	125019	10,160,747	2037-03-15	Patent claims search
Acrotech Biopharma Inc.	ZEVALIN	ibritumomab tiuxetan	Injection	125019	10,179,770	2034-03-13	Patent claims search

International Patents for ZEVALIN

Country	Patent Number	Estimated Expiration
Montenegro	00783
Eurasian Patent Organization	201071300
Canada	2626859
European Patent Office	0669836
South Africa	200106750
Cyprus	1108271

Supplementary Protection Certificates for ZEVALIN

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
SPC/GB04/025	United Kingdom		PRODUCT NAME: IBRITUMOMAB COMPRISING A CHELATING AGENT FOR YTTRIUM (90); REGISTERED: UK EU/1/03/264/001 20040116
SZ 16/2004	Austria		PRODUCT NAME: IBRITUMOMAB TIUXETAN
91089	Luxembourg		91089, EXPIRES: 20181112
2004C/016	Belgium		PRODUCT NAME: IBRITUMOMAB; AUTHORISATION NUMBER AND DATE: EU/1/03/264/001 20040119
CA 2009 00043	Denmark		PRODUCT NAME: RITUXIMAB; NAT. REG. NO/DATE: EU 1/98/067/001-002 19980602; FIRST REG. NO/DATE: CH IKS 54378 01 19971127
122004000036	Germany		PRODUCT NAME: IBRITUMOMAB TIUXETAN; REGISTRATION NO/DATE: EU/1/03/264/001 20040116

Market Dynamics and Financial Trajectory for the Biologic Drug: ZEVALIN

Last updated: September 23, 2025

Introduction

ZEVALIN (ibritumomab tiuxetan) is a monoclonal antibody radiopharmaceutical approved for treating certain CD20-positive B-cell non-Hodgkin lymphoma (NHL) subtypes. Since its FDA approval in 2002, ZEVALIN has carved a niche within the niche of targeted oncology treatments, blending immunotherapy with radiotherapy. As a pioneer in radioimmunotherapy, ZEVALIN’s market trajectory reflects evolving cancer treatment paradigms, competitive dynamics, regulatory adjustments, and broader healthcare trends.

Market Landscape and Therapeutic Positioning

ZEVALIN primarily targets follicular lymphoma, a subtype accounting for approximately 70% of indolent NHL cases [1]. Its mechanism—delivering targeted radiation via anti-CD20 antibody—positions it uniquely against conventional chemotherapies and newer biologics like CAR T-cell therapies.

Despite its initial promise, ZEVALIN faces stiff competition from multiple fronts:

• Traditionally Used Treatments: Chemotherapy and immunotherapy agents (e.g., rituximab) remain first-line, with ZEVALIN often positioned for relapsed or refractory cases due to its specialized application.
• Emerging Therapies: Novel agents such as bispecific T-cell engagers (e.g., blinatumomab), antibody-drug conjugates (e.g., polatuzumab vedotin), and CAR T-cell therapies (e.g., axicabtagene ciloleucel) are gaining ground, offering patients higher response rates and potentially curative outcomes [2].

The niche for ZEVALIN persists, especially as a treatment option for patients ineligible for aggressive therapies, but its market share is influenced significantly by these therapeutic alternatives.

Market Dynamics

Regulatory and Reimbursement Factors

ZEVALIN’s market penetration is affected by regulatory considerations. The drug's orphan status and its relatively niche indication provide some market protection. However, the lack of recent label expansions and minimal promotional activity curtail its growth potential.

Reimbursement policies further influence utilization. While some payers facilitate access for suitable patients, reimbursement complexities and the necessity for specialized facilities to handle radioactive drugs limit widespread adoption.

Supply Chain and Manufacturing

The production of radiopharmaceuticals like ZEVALIN requires specialized facilities to ensure safety and efficacy. Supply constraints, logistical challenges, and the high costs of manufacturing have historically hindered broader adoption.

Physician and Patient Acceptance

Physicians' familiarity with ZEVALIN remains moderate, often relegated to specialized nuclear medicine or hematology-oncology centers. Patient awareness of this treatment modality is relatively low compared to oral chemotherapies and targeted biologics, affecting demand.

Financial Trajectory

Sales Performance and Revenue Streams

ZEVALIN’s peak sales occurred in the early 2000s, coinciding with its initial approval and clinical enthusiasm. However, subsequent years saw a decline:

• Peak Revenue (2005–2010): Annual sales reached approximately $130 million [3].
• Decline Post-2010: Contraction owing to competition, limited label expansion, and reimbursement hurdles.
• Recent Trends (2020–2022): Estimated annual sales have fallen below $50 million, reflecting its niche status (though precise figures are underreported due to manufacturer confidentiality).

Impact of Pharmaceutical Strategies

The original manufacturer, Spectrum Pharmaceuticals, acquired rights from Genome Therapeutics and subsequently transitioned ZEVALIN's commercialization. Market strategy has been cautious, with minimal aggressive marketing, reflecting reliance on a specialized user base.

The introduction of biosimilars or generics is implausible, given the complex radiolabeling process, protecting ZEVALIN’s exclusivity but also limiting growth opportunities.

Profitability and Investment Outlook

Given limited market expansion and stiff competition, ZEVALIN’s profitability remains modest. Future revenue streams rely heavily on:

• Expansion into new indications: No significant label expansion has occurred.
• Combination therapies: Trials combining ZEVALIN with other agents could stimulate demand.
• Regulatory re-approvals: Potential for label updates to include additional NHL subtypes or earlier lines of therapy.

Overall, the financial trajectory appears stable at a low-growth plateau, with limited upside barring significant clinical or regulatory breakthroughs.

Market Opportunities and Challenges

Opportunities

• Niche positioning: As an effective treatment for relapsed indolent NHL, especially in elderly or frail patients.
• Combination regimens: Synergies with immunotherapies or checkpoint inhibitors could rejuvenate interest.
• Regional expansion: Increasing use in emerging markets with limited access to CAR T therapies.

Challenges

• Emergence of superior therapies: CAR T-cell treatments demonstrate higher response and durability.
• Logistical complexity: Severe handling requirements constrain widespread use.
• Limited clinical trials: The lack of recent pivotal studies hampers expansion and reimbursement.

Future Outlook

While ZEVALIN’s market remains modest and mature, its role as a niche therapy persists. Market dynamics hinge on clinical developments, regulatory pathways for label expansion, and healthcare system capacity to utilize radiopharmaceuticals safely. The financial outlook suggests a plateau unless disruptive innovations or wider adoption strategies are implemented.

Key Takeaways

• ZEVALIN's market position is anchored in niche indications with limited growth potential amid fierce competition from emerging immunotherapies.
• Regulatory and reimbursement barriers, coupled with logistical challenges, restrict broader utilization.
• Revenue streams are stable but declining, signaling the need for strategic repositioning or combination approaches.
• The future of ZEVALIN may depend on clinical trials showcasing expanded indications or integrating with newer therapies to reignite interest.
• Market players should monitor advancements in radiopharmaceuticals and biologic therapies to identify potential niche opportunities for ZEVALIN's repositioning.

FAQs

1. What are the main indications for ZEVALIN therapy?
ZEVALIN is primarily used for treating relapsed or refractory follicular non-Hodgkin lymphoma and transformed low-grade lymphoma in patients who have received at least two prior therapies [4].

2. How does ZEVALIN compare to other B-cell lymphoma treatments?
ZEVALIN offers targeted radiotherapy with a favorable safety profile in specific settings, especially for patients unsuitable for aggressive chemotherapy. However, newer immunotherapies and CAR T-cell products often demonstrate higher response rates and durability but may have greater toxicity and logistical hurdles.

3. Are there ongoing clinical trials involving ZEVALIN?
Limited recent trials focus on combination regimens or new indications. Ongoing research aims to assess its efficacy with lenalidomide, checkpoint inhibitors, or in earlier treatment lines [5].

4. What are the logistical challenges associated with ZEVALIN?
Handling requirements for radioactive materials, necessary specialized facilities, and coordination with nuclear medicine departments pose significant logistical hurdles, limiting rapid or widespread deployment.

5. What is the outlook for ZEVALIN's market growth?
Absent significant clinical or regulatory advancements, ZEVALIN’s market is expected to remain niche and mature, with limited growth prospects driven primarily by clinical niche applications rather than aggressive expansion.

---

References:

1. National Cancer Institute. Non-Hodgkin Lymphoma Treatment (PDQ®). 2022.
2. Park, Y. et al. Emerging therapies in B-cell lymphomas. Oncology Reports. 2021.
3. PharmaIntelligence. BIOTECH/PHARMA—ZEVALIN revenues and market data. 2022.
4. FDA. ZEVALIN (ibritumomab tiuxetan) Prescribing Information. 2021.
5. ClinicalTrials.gov. Ongoing studies involving ZEVALIN. 2022.